VistaGen Therapeutics, Inc. P/S ratio

P/S ratio of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/S ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its sales per share. It is used by investors mainly because it’s less volatile than P/E and less subject to accounting manipulation. A low P/S ratio compare to historical average or other companies in the same industry might indicate undervaluation.


Highlights and Quick Summary

Current P/S ratio of VistaGen Therapeutics, Inc. is 7.68 (as of March 30, 2017)
  • P/S ratio for the quarter ending December 30, 2020 was 74.98 (a 259.79% increase compared to previous quarter)
  • Year-over-year quarterly P/S ratio decreased by -81.2%
  • Annual P/S ratio for 2017 was 7.68 (a -97.48% decrease from previous year)
  • Annual P/S ratio for 2013 was 304.25 (a -49.43% decrease from previous year)
  • Annual P/S ratio for 2012 was 601.68 (a Infinity% increase from previous year)
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/S ratio of VistaGen Therapeutics, Inc.

Most recent P/S ratioof VTGN including historical data for past 10 years.

Interactive Chart of P/S ratio of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. P/S ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 74.98 20.84
2017 7.68
2016 16.27
2013 304.25
2012 398.91 601.68 601.68
2011 810.95 486.4 282.98 0.0 0.0
2010 0.0 0.0

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.